Cargando…

Synergistic SNGI-TKI combination against LSCs

Detalles Bibliográficos
Autor principal:	Jiang, Xiaoyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559165/ https://www.ncbi.nlm.nih.gov/pubmed/28758894 http://dx.doi.org/10.18632/aging.101272

Ejemplares similares

Post-LSCS uterocutaneous fistula-utility of magnetic resonance imaging in its diagnosis
por: Ilyas, Mohd, et al.
Publicado: (2019)

Synthesis and Spectroscopic Characterization of Thienopyrazine-Based Fluorophores for Application in Luminescent Solar Concentrators (LSCs)
por: Yzeiri, Xheila, et al.
Publicado: (2021)

Response to comments on ‘Hypertension and tachycardia following high spinal anaesthesia during LSCS: An unusual presentation’
por: Chatterjee, Protiti, et al.
Publicado: (2023)

Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
por: Zahran, Asmaa M., et al.
Publicado: (2018)

Synergistic immunotoxin-paclitaxel combination against lymphoma
por: Müller, Fabian
Publicado: (2017)

Why I Can’t Breastfeed My New-born Baby? Psychosocial Dilemma of a COVID-Positive Post-LSCS Mother
por: Kumar, Sanjeev, et al.
Publicado: (2020)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

Efficacy of ondansetron and palonosetron in prevention of shivering under spinal anesthesia: A prospective randomized double-blind study in patients undergoing elective LSCS
por: Sharma, Manoj K, et al.
Publicado: (2021)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Adjuvant TKI treatment of EGFR-mutant lung cancer—already ripe for decision?
por: Kauffmann-Guerrero, Diego
Publicado: (2020)

Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer
por: Wang, Haocheng, et al.
Publicado: (2020)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
por: Lei, Jin, et al.
Publicado: (2022)

TKI safety
por: Hjorth-Hansen, Henrik
Publicado: (2019)

Combination Therapy with PIK3R3-siRNA and EGFR-TKI Erlotinib Synergistically Suppresses Glioblastoma Cell Growth In Vitro
por: Amini, Razieh, et al.
Publicado: (2021)

Mechanisms of gefitinib-induced interstitial pneumonitis: why and how the TKI perturbs innate immune systems?
por: Kagi, Tomohiro, et al.
Publicado: (2021)

Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients
por: Chen, Yi, et al.
Publicado: (2023)

Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more
por: Zahoor, Haris, et al.
Publicado: (2017)

Alternative splicing of HER2: a novel mediator of EGFR TKI resistance
por: Yochum, Zachary A., et al.
Publicado: (2020)

Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
por: Arulananda, Surein, et al.
Publicado: (2020)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
por: Xu, Chenyue, et al.
Publicado: (2022)

The TKI Era in Chronic Leukemias
por: De Novellis, Danilo, et al.
Publicado: (2021)

Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models
por: Muselli, Fabien, et al.
Publicado: (2021)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
por: Zhao, Lihao, et al.
Publicado: (2019)

Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
por: Li, Xin, et al.
Publicado: (2020)

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI
por: Matsushita, Maiko, et al.
Publicado: (2015)

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases
por: Wang, Chunyu, et al.
Publicado: (2019)

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy
por: Fang, Wenfeng, et al.
Publicado: (2020)

Synergistic effect of CD47 blockade in combination with cordycepin treatment against cancer
por: Feng, Chen, et al.
Publicado: (2023)

Synergistic Activity of Fluoroquinolones Combining with Artesunate Against Multidrug-Resistant Escherichia coli
por: Wei, SiMin, et al.
Publicado: (2020)

Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer
por: Morales-Kastresana, Aizea, et al.
Publicado: (2014)

Synergistic activity of the combination of falcarindiol and itraconazole in vitro against dermatophytes
por: Kan, Siyue, et al.
Publicado: (2023)

Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
por: Kudo, Masatoshi
Publicado: (2022)

Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade
por: Ishibashi, Kei, et al.
Publicado: (2017)

Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC
por: Zhou Tran, Yan, et al.
Publicado: (2020)

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
por: Russo, Alessandro, et al.
Publicado: (2020)

Growth effect of tki treatment in childhood CML
por: Jeon, Yeon Jin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_edh0i8a1m71r0dgqmublequuau